XOMA (XOMA) Peer Comparison

$40.17

$0.00 (0.00%)

As on 21-Jul-2026 09:30EDT

Market cap

$710 Mln

Revenue (TTM)

$36 Mln

P/E Ratio

25.6

P/B Ratio

6.3

Div. Yield

0 %

Edit

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	710	16,504	17,747	14,622	12,501
Revenue ($ Mln)	36	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	31.51	491.50	755.85	860.62	-325.10
Net Margin (%)	86.97	17.67	71.69	35.33	-25.32
RoE (%)	28.53	110.09	--	42.98	-57.72
Price to Earnings	25.59	34.72	20.93	18.56	--
Price-To-Book	6.29	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	36.23	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	3.31	1,982.07	103.47	85.67	109.42
Gross Profit	49.18	760.62	588.53	2,236.43	902.26
Operating Expenses	28.82	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	4.98	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	33.91	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.10	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	31.51	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	112.90	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	125.89	187.89	384.48	288.55	346.72
Current Liabilities	33.08	1,435.43	464.70	361.93	374.20
Total Liabilities	272.70	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	153.11	1,006.90	895.24	1,243.41	45.47
Current Assets	118.75	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	272.70	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	124.73	120.10	449.89	165.93	347.75
Net Current Assets	85.67	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	2.87	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	50.89	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	-26.46	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	14.53	53.56	-30.01	32.82	-31.49
ROE (%)	28.53	110.09	163.18	42.98	-57.72
ROA (%)	11.71	15.64	31.68	29.32	-22.97
EBIT Margin (%)	129.28	21.13	5.73	31.04	-18.97
Net Margin (%)	86.97	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-3.33	24.67	114.85	9.23	149.04
EBIT Growth (%)	408.50	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	1,202.10	17.50	378.76	42.89	-15.32
EPS Growth (%)	741.28	26.84	353.27	50.42	-0.64
Book Value Growth (%)	12.83	164.02	816.12	-0.70	-42.66

Valuation Ratios

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	15.17	36.06	-59.76	15.79	-45.32
Price / Book Value	4.63	38.18	10.51	7.95	23.94
Dividend Yield (%)	--	0.00	0.00	0.00	0.00
EV/EBITDA	11.07	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.79	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.15	0.00	0.05	0.00	0.00
Current Ratio	3.59	0.73	2.99	3.46	3.20
Quick Ratio	3.59	0.73	2.32	3.38	2.94
Interest Coverage	3.62	--	1.62	--	-9.32

Operating Efficiency Ratios

	XOMA (XOMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	64.36	15.88	21.25	13.74	14.98
Asset Turnover	0.13	0.89	0.44	0.83	0.91
Receivable days	76.73	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	201.13	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly